DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening with Clinically Vetted Compounds

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) comprises 2,320 bioactive compounds, each clinically approved by regulatory agencies such as the FDA, EMA, HMA, CFDA, and PMDA, or listed in established pharmacopeias [APExBIO Product Page]. All compounds are pre-dissolved at 10 mM in DMSO and validated for stability up to 12 months at –20°C and 24 months at –80°C. The library is formatted for high-throughput and high-content screening, facilitating drug repositioning and identification of novel pharmacological targets (Alexander-Howden et al., 2023). Representative drugs include doxorubicin, metformin, and atorvastatin, supporting wide-ranging research applications. The resource is actively used in cancer research, neurodegeneration studies, and pathway analysis, with robust documentation and verifiable compound annotation (Gens-Bio Article).

Biological Rationale

High-throughput screening (HTS) and high-content screening (HCS) require compound libraries with well-characterized safety and mechanism-of-action profiles. The DiscoveryProbe™ FDA-approved Drug Library addresses this need by assembling 2,320 compounds that have undergone extensive clinical evaluation and regulatory approval. These molecules span diverse pharmacological classes, including receptor agonists/antagonists, enzyme inhibitors, ion channel modulators, and signaling pathway regulators [APExBIO]. Clinically vetted compounds reduce the risk of off-target toxicity and facilitate direct translation from bench to bedside. The inclusion of drugs with established safety profiles enhances hit-to-lead validation, especially in phenotypic screens for cancer, neurodegenerative disorders, and rare diseases (Alexander-Howden et al., 2023).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

Compounds in the DiscoveryProbe™ library act through diverse mechanisms, including:

• Receptor Agonists/Antagonists: Targeting G protein-coupled receptors, nuclear hormone receptors, and neurotransmitter receptors (e.g., metformin as an AMPK activator).
• Enzyme Inhibitors: Inhibiting kinases, phosphatases, proteases, and metabolic enzymes (e.g., doxorubicin as a topoisomerase II inhibitor).
• Ion Channel Modulators: Regulating calcium, sodium, and potassium channels critical in cardiac and neurological function.
• Signal Pathway Regulators: Modulating Wnt, MAPK, PI3K/AKT, and NF-κB pathways.

By providing a spectrum of validated mechanisms, the library supports multidimensional screening across disease models, enabling both target-based and phenotypic discovery strategies (Amyloid-Peptide Article). This article extends previous analyses by providing mechanistic granularity and detailed workflow integration steps.

Evidence & Benchmarks

• In a luminescence-based screening for MeCP2-TBL1 interaction inhibitors, the DiscoveryProbe™ library enabled robust assay performance, with a Z-factor of 0.85 (indicative of excellent separation between positive and negative controls) (Alexander-Howden et al., 2023).
• Compounds from the library were used to identify small-molecule disruptors of protein–protein interactions relevant to neurodevelopmental disorders (Scientific Reports, 2023).
• The library’s pre-dissolved 10 mM DMSO format showed chemical stability for at least 12 months at –20°C and 24 months at –80°C according to manufacturer documentation (APExBIO).
• High-content screens using the library have facilitated rapid identification of candidate drugs for repositioning in oncology and neurodegenerative disease models (Gens-Bio Article).
• Independent benchmarking confirms the utility of this collection for pathway analysis and drug mechanism-of-action studies (Angiotensin-III Article).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is applicable in:

• High-throughput screening for drug repositioning across oncology, neurodegenerative, and infectious disease models.
• Pharmacological target identification and validation in both cellular and biochemical assays.
• Signal pathway regulation studies, leveraging known modulators for rapid mechanistic elucidation.
• Combination therapy discovery, including assessment of synergistic or antagonistic drug interactions.

This article clarifies and updates previous discussions by emphasizing the importance of regulatory-vetted compound selection and robust annotation—contrasting with DZNEP Article, which focused on format and workflow ease.

Common Pitfalls or Misconceptions

• The library does not include investigational (non-approved) or preclinical-only compounds; all entries are regulatory-approved or pharmacopoeia-listed.
• Not all compounds are suitable for every disease model due to specific mechanism-of-action or tissue distribution limitations.
• Use in in vivo animal models requires reformulation; the supplied DMSO solutions are intended for in vitro assays.
• Biological effects observed may reflect polypharmacology, not single-target specificity; orthogonal validation is necessary.
• The library is not a substitute for de novo chemical diversity libraries in primary hit discovery campaigns.

Workflow Integration & Parameters

Researchers can integrate the DiscoveryProbe™ FDA-approved Drug Library into HTS pipelines using standard 96-well or deep-well microplate formats. Each compound is delivered as a 10 mM stock in DMSO for direct dilution. Storage at –20°C (up to 12 months) or –80°C (up to 24 months) is recommended to maintain compound integrity. Shipping options include blue ice or room temperature, as requested. Screening concentrations typically range from 1 μM to 10 μM, adjusted based on assay sensitivity and cell type. Data output is compatible with automated liquid handling and high-content imaging systems. For detailed workflow guidance, see Rhodopsin-Peptide Article, which focuses on neurodegenerative disease research; this article supplements that by providing application guidance for oncology and combination therapy screening.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library from APExBIO is a validated resource for high-throughput and high-content screening. Its clinically approved, well-annotated compounds accelerate drug repositioning, target identification, and mechanistic studies. The library’s ready-to-use format and robust documentation support reproducible research across diverse biomedical domains. Future updates may include expansion to newly approved drugs and integration with AI-driven screening platforms. For further details or ordering, visit the DiscoveryProbe™ FDA-approved Drug Library product page.